JIP
NVAX icon

Jaffetilchin Investment Partners’s Novavax NVAX Stock Holding History

Jaffetilchin Investment Partners’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10
Closed -$126 – 966
2024
Q3 		$126 Buy
+10
New +$129 ﹤0.01% 1330

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Jaffetilchin Investment Partners's NVAX Position: Q4 2024 in Review

Jaffetilchin Investment Partners sold out of Novavax (NVAX) in Q4 2024, closing a stake of 10 shares — an estimated $126 sold.

Jaffetilchin Investment Partners first reported a position in NVAX in Q3 2024 and held it in 1 quarter. The position peaked at $126 in Q3 2024. 235 funds tracked by Wall St. Rank hold NVAX as of Q4 2024.

  • Jaffetilchin Investment Partners reported no remaining Novavax position as of Q4 2024 after selling out during the quarter.
  • Jaffetilchin Investment Partners sold 10 Novavax shares in Q4 2024, an estimated $126.
  • Jaffetilchin Investment Partners first reported a position in Novavax in Q3 2024 and held it in 1 quarter.
  • Jaffetilchin Investment Partners's Novavax position peaked at $126 in Q3 2024.
  • 235 funds tracked by Wall St. Rank held Novavax as of Q4 2024.

Based on Jaffetilchin Investment Partners's 13F filing for Q4 2024, filed 13 Feb 2025.